HOME >> MEDICINE >> NEWS
International breast cancer prevention study launches in the United States and Canada

es national and international trials of cancer therapy, including trials for new cancer drugs, cancer prevention and supportive care to improve quality of life for people with cancer. Since its inception, the NCIC CTG has enrolled more than 40,000 patients from Canada and around the world in over 300 clinical trials.

Pfizer, Inc. manufactures exemestane under the brand name Aromasin and is providing the drug for the trial.

Women looking for more information about the ExCel research study and participating study centers in their community can visit www.excelstudy.com or call toll-free:

  • In the U.S. 1-800-4-CANCER
  • In Canada 1 888 939-3333

    About Exemestane

    Exemestane (Aromasin) was approved in the United States late in 1999 for the treatment of advanced breast cancer in postmenopausal women whose tumors have stopped responding to tamoxifen. Exemestane is approved by the FDA and Health Canada and is marketed by Pfizer, Inc. as Aromasin. It is also approved for use in Europe, Japan, and South America. It is currently used for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

    Results of the Intergroup Exemestane Study, published in the New England Journal of Medicine, revealed that 32 percent fewer women had a recurrence in their breast cancer when they switched to exemestane after two to three years of tamoxifen compared to those who continued on tamoxifen for a total of five years, the current standard of care. Additionally, twice as many women receiving tamoxifen developed second (or new) breast cancers than those treated with exemestane.

    Unlike other aromatase inhibitors, exemestane is a steroidal aromatase inactivator, which means it selectively targets and irreversibly binds to the aromatase enzyme, which is required to produce estrogen. Without estrogen, breast can
    '"/>



  • Contact: Samantha Kaplan
    samantha.kaplan@edelman.com
    312-297-7439
    Edelman Public Relations
    30-Mar-2005


    Page: 1 2 3 4

    Related medicine news :

    1. National Academies advisory: May 2 Symposium on International Science Policy
    2. Awards & fellowships at the International & American Association for Dental Research General Session
    3. Lectures, keynoters, symposia highlight International Dental Research meeting
    4. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
    5. International gathering of experts to share retinoblastoma breakthroughs
    6. International trial of two microbicides begins
    7. International gathering at UH examines top computer code
    8. International trial finds benefits of breast MRI in women at high risk
    9. International study provides culture-by-culture clues to family violence and abuse
    10. St. Jude scientist wins International Society of Experimental Hematology award
    11. International MRC trial finds a routine treatment for head injury may do more harm than good

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
    (Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
    (Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
    (Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
    Breaking Medicine News(10 mins):
    (Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
    (Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
    (Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
    Breaking Medicine Technology:
    Cached News: